Direct T cell activation via CD40 ligand generates high avidity CD8 + T cells capable of breaking immunological tolerance for the control of tumors

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Soong, Ruey Shyang ^a,b,c   Song, Liwen ^a,d,e,f   Trieu, Janson ^g   Lee, Sung Yong ^a,h   He, Liangmei ^a   Tsai, Ya Chea ^a   Wu, T C ^a   Hung, Chien Fu ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d FUDAN UNIVERSITY   (China)

^e SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^f TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h Korea University Ansan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; DNA VACCINE; GLYCOPROTEIN GP 100; PROTEIN BCL XL; PROTEIN P53; TUMOR ANTIGEN; CANCER VACCINE; MELANOCYTE PROTEIN PMEL 17;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; ELECTROPORATION; ENZYME ACTIVATION; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION; VACCINATION; ANIMAL; ANTIGEN PRESENTING CELL; GENETICS; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GP100 MELANOMA ANTIGEN; IMMUNE TOLERANCE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899735764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093162     Document Type: Article

References (51)

1. Disis ML, Bernhard H, Jaffee EM (2009) Use of tumour-responsive T cells as cancer treatment. Lancet 373: 673-683.
2. Bourgeois C, Rocha B, Tanchot C (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297: 2060-2063.
3. Johnson S, Zhan Y, Sutherland RM, Mount AM, Bedoui S, et al. (2009) Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity 30: 218-227.
4. Seah SG, Brady JL, Carrington EM, Ng WC, Sutherland RM, et al. (2013) Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response. J Leukoc Biol 93: 145-154.
5. Loskog A, Totterman TH (2007) CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7: 23-28. (Pubitemid 46380415)
6. Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW (2012) The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 31: 246-266.
7. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
8. Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, et al. (2013) Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 54: 277-283.
9. de Gruijl TD, Luykx-de Bakker SA, Tillman BW, van den Eertwegh AJ, Buter J, et al. (2002) Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 169: 5322-5331. (Pubitemid 35217206)
10. Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, et al. (2010) Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. J Immunother 33: 706-715.
11. Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, et al. (2012) CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic. J Gene Med 14: 416-427.
12. Ishizaki H, Song GY, Srivastava T, Carroll KD, Shahabi V, et al. (2010) Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother 33: 609-617.
13. Lane DP, Cheok CF, Lain S (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2: a001222.
14. Nemunaitis J, Nemunaitis J (2011) Head and neck cancer: response to p53-based therapeutics. Head Neck 33: 131-134.
15. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
16. Machado-Silva A, Perrier S, Bourdon JC (2010) p53 family members in cancer diagnosis and treatment. Semin Cancer Biol 20: 57-62.
17. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569-580. (Pubitemid 37040391)
18. Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23: 421-429.
19. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, et al. (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27: 5450-5459.
20. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, et al. (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188: 277-286. (Pubitemid 28357756)
21. Fox BA, Spiess PJ, Kasid A, Puri R, Mule JJ, et al. (1990) In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod 9: 499-511. (Pubitemid 20366163)
22. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, et al. (2000) High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 60: 5508-5513.
23. Kim TW, Hung CF, Boyd D, Juang J, He L, et al. (2003) Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 171: 2970-2976. (Pubitemid 37093519)
24. Kim TW, Lee JH, He L, Boyd DA, Hung CF, et al. (2005) DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum Gene Ther 16: 26-34. (Pubitemid 40250329)
25. Pedersen SR, Sorensen MR, Buus S, Christensen JP, Thomsen AR (2013) Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J Immunol 191: 3955-3967.
26. Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO (2005) Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11: 435-443. (Pubitemid 40277320)
27. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, et al. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26. (Pubitemid 26010379)
28. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, et al. (1999) Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 10: 2727-2740.
29. Chang CL, Wu TC, Hung CF (2007) Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther 14: 1189-1198.
30. Hung CF, Tsai YC, He L, Wu TC (2007) Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther 14: 921-929. (Pubitemid 46865503)
31. Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, et al. (2006) Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther 5: 2592-2599. (Pubitemid 44650924)
32. Soong RS, Trieu J, Lee SY, He L, Tsai YC, et al. (2013) Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PLoS One 8: e56912.
33. Kato K, Cantwell MJ, Sharma S, Kipps TJ (1998) Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101: 1133-1141. (Pubitemid 28125292)
34. Kang TH, Mao CP, He L, Tsai YC, Liu K, et al. (2012) Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects. PLoS One 7: e35141.
35. Dahl AM, Beverley PC, Stauss HJ (1996) A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol 157: 239-246. (Pubitemid 26190553)
36. Suzuki I, Fink PJ (1998) Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med 187: 123-128. (Pubitemid 28044827)
37. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, et al. (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678. (Pubitemid 32906195)
38. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, et al. (2009) Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206: 849-866.
39. Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayoitidis P, Pilling D, et al. (1996) Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 26: 294-299.
40. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, et al. (2003) Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 5: 733-740. (Pubitemid 36986781)
41. Boise LH, Thompson CB (1997) Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc Natl Acad Sci U S A 94: 3759-3764.
42. Mueller SN, Gebhardt T, Carbone FR, Heath WR (2013) Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 31: 137-161.
43. Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5: 508-515. (Pubitemid 38660463)
44. DeBenedette MA, Calderhead DM, Ketteringham H, Gamble AH, Horvatinovich JM, et al. (2008) Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J Immunol 181: 5296-5305.
45. Cho HI, Celis E (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69: 9012-9019.
46. Aranda F, Llopiz D, Diaz-Valdes N, Riezu-Boj JI, Bezunartea J, et al. (2011) Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 71: 3214-3224.
47. Gattinoni L, Klebanoff CA, Restifo NP (2012) Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12: 671-684.
48. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, et al. (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15: 808-813.
49. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, et al. (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17: 1290-1297.
50. Suttles J, Stout RD (2009) Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol 21: 257-264.
51. Jones DS, Reichardt P, Ford ML, Edwards LJ, Evavold BD (2008) TCR antagonism by peptide requires high TCR expression. J Immunol 181: 1760-1766.